Association between Moraxella keratitis and advanced glycation end products

Hidenori Inoue1, Koji Toriyama2, Naoko Takahira2

  • 1Department of Ophthalmology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan. inoue.hidenori.yo@ehime-u.ac.jp.

Scientific Reports
|April 5, 2024
PubMed

Insights

Diabetes mellitus increases Moraxella keratitis risk. Advanced glycation end products (AGEs) in the cornea enhance Moraxella bacterial adhesion, suggesting AGEs contribute to this serious eye infection in diabetic patients.

Area of Science:

  • Ophthalmology
  • Microbiology
  • Endocrinology

Background:

  • Diabetes mellitus is a known risk factor for Moraxella keratitis.
  • The precise mechanisms linking diabetes to Moraxella keratitis are not fully understood.
  • Advanced glycation end products (AGEs) accumulate in diabetic tissues.

Purpose of the Study:

  • To investigate the impact of advanced glycation end products (AGEs) deposition in the cornea on Moraxella bacterial adhesion.
  • To explore the role of AGEs in the pathogenesis of Moraxella keratitis in diabetic patients.

Main Methods:

  • Retrospective analysis of 27 culture-proven Moraxella keratitis cases.
  • Identification of Moraxella isolates using MALDI-TOF mass spectrometry.
  • In vitro assessment of Moraxella nonliquefaciens adherence to human corneal epithelial cells (HCECs) with and without AGEs.
  • In vivo study using streptozotocin-induced diabetic mice treated with an AGE inhibitor.

Main Results:

  • 30.4% of patients with Moraxella keratitis had diabetes mellitus.
  • Moraxella nonliquefaciens adherence to HCECs significantly increased with AGEs.
  • Pyridoxamine treatment significantly reduced Moraxella nonliquefaciens adherence in diabetic mouse corneas.

Conclusions:

  • AGEs deposition in the corneal epithelium may significantly influence the development of Moraxella keratitis.
  • Targeting AGEs could be a potential therapeutic strategy for Moraxella keratitis in diabetic individuals.